What is the starting dose of Wegovy (semaglutide) administered subcutaneously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Wegovy Starting Dose

Start Wegovy at 0.25 mg subcutaneously once weekly for the first 4 weeks, then escalate the dose every 4 weeks (0.5 mg → 1.0 mg → 1.7 mg) until reaching the maintenance dose of 2.4 mg once weekly. 1

Dose Titration Schedule

The FDA-approved dosing regimen follows a structured 16-week titration:

  • Weeks 1-4: 0.25 mg once weekly 1
  • Weeks 5-8: 0.5 mg once weekly 1
  • Weeks 9-12: 1.0 mg once weekly 1
  • Weeks 13-16: 1.7 mg once weekly 1
  • Week 17 onward: 2.4 mg maintenance dose once weekly 1

This gradual escalation is essential to minimize gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation), which are the most common side effects but typically transient and mild-to-moderate in severity. 1

Administration Details

  • Timing: Administer at any time of day, with or without meals 1
  • Route: Subcutaneous injection 2, 1
  • Frequency: Once weekly 1

Missed Dose Management

  • Less than 5 days since missed dose: Administer as soon as possible 1
  • More than 5 days since missed dose: Skip the missed dose and resume at next scheduled time 1
  • 2 consecutive doses missed: Resume at the same dose if previously well-tolerated, or consider lowering the dose 1
  • 3 or more consecutive doses missed: Consider restarting the entire titration schedule 1

Special Populations

No dosage adjustment required for renal impairment, including patients with end-stage renal disease. 2, 1 This is a significant advantage over some other weight management medications.

Clinical Pearls

Some patients achieve significant weight loss at submaximal doses (e.g., 1.0 mg or 1.7 mg) and may continue at that dose long-term rather than escalating to 2.4 mg. 1 The STEP trials demonstrated mean weight losses of 14.9%-17.4% at the 2.4 mg maintenance dose, with 69%-79% of participants achieving ≥10% weight loss. 3

Drug Interactions to Avoid

  • Do not combine with other GLP-1 receptor agonists (e.g., liraglutide, dulaglutide) 1
  • Do not combine with DPP-4 inhibitors 1
  • Use caution with insulin or insulin secretagogues due to hypoglycemia risk; dose adjustments of these medications may be needed 1

References

Guideline

Recommended Dosing Regimen for Wegovy (Semaglutide)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.